Photochemical Control of the Infectivity of Adenoviral Vectors Using a Novel Photocleavable Biotinylation Reagent  by Pandori, Mark W et al.
Chemistry & Biology, Vol. 9, 567–573, May, 2002, 2002 Elsevier Science Ltd. All rights reserved. PII S1074-5521(02)00135-7
Photochemical Control of the Infectivity
of Adenoviral Vectors Using a Novel
Photocleavable Biotinylation Reagent
range of adenoviral vectors has two consequences that
limit their utility for in vivo gene transfer applications,
such as gene therapy. First, their broad tropism can
result in the delivery of the transgene in a nonspecific
manner. Second, large doses of undirected adenoviral
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infectivity of adenoviral vectors. This strategy involves
a method whereby the infectivity of an adenoviral vector
is first neutralized by a reversible chemical modification.Summary
Reversal of this chemical modification allows for the
restoration of infectivity to the adenoviral vector. ThisWe have explored a novel strategy for controlling the
strategy had recently been successfully implementedinfectivity of adenoviral vectors. This strategy involves
on retroviral vectors derived from amphotropic Moloneya method whereby the infectivity of adenoviral vectors
murine leukemia virus by using photocleavable biotinis neutralized by treatment of viral particles with a
(PCB) [6] as the modification reagent [7]. PCB (Figurewater-soluble, photocleavable biotinylation reagent.
1A) contains a biotin moiety linked though a spacer armThese modified viral vectors possess little to no in-
to a 1-(2-nitrophenyl)ethyl group, which is derivatizedfectivity for target cells. Exposure of these modified
with an NHS (N-hydroxysuccinimide) ester. The NHSviral vectors to 365 nm light induces a reversal of the
ester reacts selectively with primary aliphatic aminoneutralizing, chemical modification, resulting in resto-
groups, such as N termini and lysine residues on pro-ration of infectivity to the viral vectors. The light-
teins, which are abundant in viral vectors, to form adirected transduction of target cells by photoactivata-
carbamate bond. When PCB-biomolecule conjugatesble adenoviral vectors was demonstrated successfully
are exposed to 300–365 nm light, the PCB moiety under-both in vitro and in vivo. This photochemical infectivity
goes an intramolecular photochemical reaction, whichtrigger possesses great potential, both as a research
involves the cleavage of the carbamate bond. This re-tool and as a novel tactic for the delivery of gene-
sults in the regeneration of the primary amino group ontransfer agents, since the infectivity of adenoviral vec-
the biomolecule and releases the PCB moiety, in whichtors can be controlled externally in a versatile manner.
the 1-(2-nitrophenyl)ethyl group is converted to a 2-nitro-
soacetophenone derivative [6]. PCB is highly hydro-Introduction
phobic and exhibits low solubility in aqueous media. To
reduce hydrophobicity and increase solubility in aqueousAdenoviral vectors have become one of the most useful
media, a water-soluble version of PCB (WSPCB) was syn-gene transfer agents [1–5]. They are structurally stable
thesized. WSPCB is structurally similar to PCB, but itand can be produced to high infectious titers (up to
has a mixed polarity spacer arm between the biotin and1012 infectious units/ml). Their genome can be easily
1-(2-nitrophenyl)ethyl moieties (Figure 1A). The synthe-manipulated to deliver large transgenes. Adenoviral vec-
sis of WSPCB (Figure 1B) involved the production oftors can infect a wide range of cells, including nondivid-
a mono-biotinylated derivative of 2,2’-(ethylenedioxy)-ing cells. These characteristics make adenoviral vectors
bis(ethylamine), which was then conjugated to 5-succi-a particularly attractive tool for a wide variety of gene
nylamidomethyl-2-nitroacetophenone. The resulting in-transfer applications. However, the broad target cell
termediate was converted to a reactive NHS derivative.
In order to determine if the infectivity of adenoviral6 Correspondence: tsano@caregroup.harvard.edu
7 These authors contributed equally to this work. vectors could be eliminated by treatment with either
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Figure 1. Structures and Synthesis of Photocleavable Biotins
(A) Structures of photocleavable biotin (NHS-PC-LC-Biotin; PCB) and its water-soluble derivative, WSPCB.
(B) Synthesis scheme of WSPCB.
PCB or WSPCB, adenoviral vectors were exposed to because of damage to adenoviral vectors caused by
shorter-wavelength radiation emitted from the UV lightvarious concentrations of PCB or WSPCB. The adenovi-
ral vectors used contain a transducable lacZ gene, source.
We next attempted to determine whether the reactiva-which provides a simple means of detecting transduced
cells. Treatment with WSPCB at 1 mg/ml or greater virtu- tion of adenoviral infectivity could be done in situ in the
presence of target cells. Adenoviral vectors treated withally eliminated the infectivity of these vectors (Figure
2A). In contrast, treatments with PCB were considerably 1 mg/ml WSPCB were added to D-17 cells growing in
borosilicate glass vials. These vials were either kept inless effective at inhibiting the infectivity of these vectors
than with WSPCB at the same concentrations (Figure the dark or irradiated with 365 nm light. Infection assays
of cells, which had been exposed to WSPCB-treated2B). Retroviral vectors, when treated with PCB, showed
a behavior contrary to this finding [7]. PCB was highly adenovirus vectors and kept in the dark, showed negligi-
ble amounts of infection, while great amounts of infec-effective at abrogating retroviral infectivity at concentra-
tions of 1–2 mg/ml. This differential sensitivity of retrovi- tion were observed in cells exposed to WSPCB-treated
adenoviral vectors and irradiated with 365 nm light (Fig-ral and adenoviral vectors to these two biotinylation
reagents may be derived from the vast differences in ure 4). Irradiation with 365 nm light showed no apprecia-
ble effects on cell viability. These experiments were per-the structures and properties of the outer surfaces of
these viruses. Having observed the sensitivity of the formed by using WSPCB-treated adenoviral vectors,
which had been washed of free, unreacted WSPCBadenoviral vectors to biotinylation by WSPCB, we deter-
mined the concentration range in which WSPCB could by repeated rounds of ultrafiltration. This ensured that
the photoactivatable infectivity of adenoviral vectors,function to modulate viral infectivity (Figure 2C). Treat-
ment with as low as 0.1 mg/ml WSPCB reduced infec- shown above, would not be based on the presence of
non-virion-associated WSPCB.tivity by nearly 50%. Treatment with WSPCB at concen-
trations greater than 0.4 mg/ml virtually eliminated the The results described above imply that WSPCB is
covalently attached to viral particles upon treatment andinfectivity of these vectors.
We tested whether the infectivity of the biotinylated that the association of WSPCB with virions is responsi-
ble for the photoactivatable infectivity of treated vectors.adenoviral vector could be recovered via photocleavage
of the WSPCB molecule from the viral particles. Adeno- To determine whether WSPCB is associated with viri-
ons, and, if so, whether irradiation with 365 nm lightviral vectors were treated with various concentrations
of WSPCB, and then either kept in the dark or exposed causes cleavage of virion-associated WSPCB, Western
blotting analysis was performed. Adenoviral vectorsto 365 nm light. These samples were analyzed for their
infectivity by using D-17 cells (Figure 3A). WSPCB- were treated with 1 mg/ml WSPCB and either irradiated
with 365 nm light or kept in the dark. The resulting viraltreated, nonirradiated adenoviral vectors showed virtu-
ally no infectivity. In contrast, when WSPCB-treated viral proteins were separated by SDS-PAGE (sodium dodecyl
sulfate-polyacrylamide gel electrophoresis), transferredvectors were exposed to 365 nm light, their infectivity
was restored. At an energy output of 16 mW/cm2 , resto- to a membrane, and probed for conjugated WSPCB with
a streptavidin-alkaline phosphatase conjugate (Figureration of infectivity occurred within 1 min of exposure
to 365 nm light, with maximum recovery occurring after 5). Biotinylation was observed on 84 kDa and 134 kDa
proteins in samples derived from WSPCB-treated, nonir-3 min of irradiation (Figure 3B). Irradiation with 365 nm
light beyond 3 min did not enhance the recovery of radiated adenoviral vectors (lane 1). The amount of
WSPCB, bound to these proteins, was markedly re-infectivity. Instead, the infectivity of irradiated vectors
decreased slightly with prolonged exposure, possibly duced when WSPCB-treated viral vectors had been ex-
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Figure 3. Photoactivation of WSPCB-Treated Adenoviral Vectors
(A) Photoactivation of the infectivity of adenoviral vectors treated
with various concentrations of WSPCB. Adenoviral vectors were
treated with various concentrations of WSPCB, placed into borosili-
cate glass vials, and either kept in the dark (solid bars) or irradiated
with 365 nm light (16 mW/cm2 ) for 3 min (hatched bars). The resulting
viral vectors were added to monolayers of D-17 cells (5  104 per
well) to analyze their infectivity.
(B) Time course of the restoration of the infectivity of WSPCB-treated
adenoviral vectors. Adenoviral vectors were treated with 1 mg/ml
WSPCB and irradiated with 365 nm light (16 mW/cm2 ) for the dura-
tions indicated. The infectivity of the irradiated viral vectors was
analyzed by using D-17 cells.
Figure 2. Effect of Treatment with WSPCB or PCB on the Infectivity
of Adenoviral Vectors the mechanism of infectivity inhibition by these reagents
is based on the modulation of the function of viral pro-A stock solution of WSPCB or PCB, both in DMF, was diluted in
PBS (pH 7.4). The diluted WSPCB or PCB (25 l) was allowed to teins on the outer, solvent-exposed viral surface. Hence
react with adenoviral vectors (2.5  106 viral particles in 25 l PBS) we hypothesized that the ability of adenoviral vectors
for 2 hr. The infectivity of the resulting viral vectors was assayed to either bind or enter target cells is disrupted upon
by using D-17 cells. DMF at concentrations used during treatment
treatment with WSPCB. To test this hypothesis, we de-with WSPCB or PCB (up to 8%) showed no effect on infectivity and
vised an assay that quantifies the ability of viral particlescell viability. (A and C), WSPCB; (B), PCB.
to be adsorbed by target cells. Adenoviral vectors were
treated with 1 mg/ml WSPCB and incubated over a
monolayer of D-17 cells in a culture dish or in an emptyposed to 365 nm light (lane 2). These results demon-
strate that irradiation of WSPCB-treated adenoviral culture dish for 3 hr. Then, culture supernatants con-
taining unbound viral vectors were collected, exposedvectors with 365 nm light cleaves and subsequently
liberates WSPCB from virions. These data strongly sug- to 365 nm light, and added to fresh D-17 cells for analysis
of infectious titers. Comparison of the infectious titers ofgest that the conjugation of WSPCB to adenoviral vec-
tors and cleavage of virion-associated WSPCB is the adenoviral vectors incubated with D-17 cells and those
incubated in an empty culture dish indicates a percent-infectivity-controlling factor.
As shown above, WSPCB is vastly more effective than age of viral vectors that were associated with the D-17
cells (Figure 6). WSPCB-treated adenoviral vectors ex-PCB in inhibiting the infectivity of adenoviral vectors.
The primary difference in properties between the two hibited minimal levels of cell association. Adenoviral
vectors, which had been treated with WSPCB and irradi-biotinylation reagents, i.e., hydrophilicity, suggests that
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Figure 6. Adsorption Assays of WSPCB-Treated Adenoviral VectorsFigure 4. In Situ Photoactivation of WSPCB-Treated Adenoviral
Vectors Adenoviral vectors were treated with 1 mg/ml WSPCB and incu-
bated for 3 hr over monolayers of D-17 cells grown in a 35 mmAdenoviral vectors were treated with 1 mg/ml of WSPCB. The re-
culture dish. The same viral vector sample was also incubated insulting viral vectors were purified away from unreacted WSPCB by
an empty 35 mm culture dish to estimate nonspecific binding ofultrafiltration, and small aliquots (1 l or 25 l) of the purified viral
virions to culture dishes. The supernatants (culture medium frac-vectors were placed within each of four 3 ml borosilicate glass vials
tions) containing unbound virions were collected and exposed tocontaining monolayers of D-17 cells (5  104 per vial) covered with
365 nm light (16 mW/cm2 ) for 3 min. Adenoviral vectors, which had500 l of DMEM/6% FBS. Two of the vials were placed in the dark
been treated with 1 mg/ml WSPCB and exposed to 365 nm light(solid bars), while the other two vials were exposed to 365 nm light
prior to the application to D-17 cells or an empty tissue culture dish,(16 mW/cm2 ) for 4 min (hatched bars). At 48 hr after irradiation, cells
were also used in the same manner. Adenoviral vectors withoutwere stained for the expression of the lacZ gene. Shown are the
WSPCB treatment were used as controls. All supernatants wereresults from two independent experiments with different viral in-
subjected to infectivity analysis using fresh D-17 cells. The percent-nocula.
age of cell-associated virions for each sample is calculated as:
[(Infectivity remaining in the supernatant after incubation in an empty
dish) – (infectivity remaining in the supernatant after incubation withated with 365 nm light prior to incubation with D-17
D-17 cells)] / (infectivity remaining in the supernatant after incubationcells, showed levels of cell association equivalent to
in an empty dish).
those of untreated adenoviral vectors. This data sug-
gests that the conjugation of WSPCB to adenoviral vec-
tors inhibits their infectivity by interfering with their abil- vectors to be used for in vivo gene transfer applications
ity to bind to target cells and that irradiation with 365 using tumors growing in nude mice as viral targets.
nm light restores the binding ability of these vectors for Athymic nude mice were each injected percutaneously
target cells by releasing virion-associated WSPCB. with D-17 cells on each side of the back of the mice
Following the successful development and character- just above the upper legs. After the formation of small
ization of photoactivatable adenoviral vectors in an in tumor nodules on both sides of the mice, tumor sites
vitro setting, we tested the potential of these adenoviral were injected with adenoviral vectors that had been
treated with 0.5 mg/ml WSPCB (these treated viral vec-
tors showed photoactivatable infectivity in vitro with
cultured D-17 cells; data not shown). The mice were
covered in an aluminum foil cloak, which was designed
and cut in a way such that only one tumor site was
exposed. Exposed tumor sites were irradiated externally
with 365 nm light for 4 min through the skin over the
tumor nodule. The mice were sacrificed at 48 hr after
irradiation, and the tumor nodules, along with adjoining
tissue, were collected, sectioned, and stained for the
expression of the lacZ gene. Sections of tumor sites
that were not exposed to 365 nm light show very few,
if any, infected cells (Figure 7). However, sections of
injected tumor sites that were irradiated with 365 nm
light through the skin show a large number of infected
cells. This indicates that the infectivity of WSPCB-
treated adenoviral vectors can be reactivated in vivo by
Figure 5. Western Blotting Analysis of WSPCB-Treated Adenoviral external photoirradiation. This also demonstrates that
Vectors the inactivation of viral infectivity with WSPCB is a modi-
Adenoviral vectors were treated with 1 mg/ml WSPCB and either fication that is not reversed under physiological, unirra-
kept in the dark (lane 1) or irradiated with 365 nm light (16 mW/cm2 ) diated conditions. Apparently, the skin did not function
for 4 min (lane 2). The resulting viral vectors were subjected to SDS-
as a complete barrier to the reactivating light. The skinPAGE, and proteins were transferred to polyvinylidene difluoride
that was positioned over the irradiated tumor sites wasmembrane. Biotinylated viral proteins were detected by using a
streptavidin-alkaline phosphatase conjugate (Pierce). also not noticeably affected by the irradiation. A control
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Figure 7. In Vivo Photoactivation of WSPCB-Treated Adenoviral Vectors
Mouse subcutaneous tumor models were prepared by using D-17 cells and athymic nude mice as described in Experimental Procedures.
After small tumor nodules (3–5 mm) formed in these mice, each tumor site was injected with WSPCB-treated adenoviral vector (250 l). Mice
were anesthetized and covered with aluminum foil with a hole to expose only the right-hand tumor sites. Exposed tumor sites were irradiated
with 365 nm light for two 2 min periods, separated by a 30 s intermission. At 48 hr after irradiation, mice were sacrificed, followed by the
collection of tumor sites with adjoining tissue. Tissue was sectioned (50 m sections), and the resulting tissue sections were stained for the
expression of the lacZ gene using X-gal as the substrate. The stained tissue sections were viewed under a light microscope. (A–C), no
irradiation (control); (D–F), irradiated with 365 nm light. A control experiment was performed in the same manner by injecting unmodified
adenoviral vectors into the tumor site (G).
experiment, in which unmodified adenoviral vectors vivo. This infectivity trigger holds considerable poten-
tial for the delivery of adenoviral vectors, since thewere injected in the same manner, showed a compara-
ble amount of infection, indicating that the reactivation site-specific activation of viral vectors could be medi-
ated by the application of 365 nm light focused on theof PC-biotin-modified adenoviral vectors by photoirradi-
ation under in vivo conditions is also highly efficient as target sites. The viral surface biotin moiety should also
be useful for further modification of the viral surface.seen with in vitro systems. These data demonstrate the
potential that WSPCB-treated adenoviral vectors can For example, biotinylated materials can be attached
to viral surface biotin moieties by using streptavidinbe used as activatable gene transfer agents in whole
animals. as a molecular bridge with little effect on the cleavage
efficiency of virion-associated PCB by photoirradi-
ation (M.W.P., D.A.H., and T.S., unpublished data).Significance
These findings offer a novel strategy to the field of
gene therapy by creating a new way to control theWe have demonstrated a method of making adenoviral
activities of viral vectors.vectors selectively activatable by an external stimulus.
Conjugation of a PCB derivative, WSPCB, virtually
Experimental Procedureseliminates the infectivity of adenoviral vectors in a
reversible manner. Exposure of WSPCB-treated viral
Adenoviral Vectors and Target Cellsvectors to 365 nm light restores infectivity to levels
The adenoviral vector used in this study, Ad5.CMV-LacZ (Qbiogene,
approaching those prior to biotinylation. Inhibition and Montreal, Canada), is derived from adenovirus serotype 5 with the
restoration of the infectivity of adenoviral vectors has deletion of the viral E1A, E1B, and E3 genes. The adenoviral vector
carries the bacterial lacZ gene (-galactosidase) under the controlsuccessfully been demonstrated both in vitro and in
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of the human cytomegalovirus immediate-early promoter. This viral 7 (67% yield). Reduction with sodium borohydride and conversion
to the target NHS carbonate were carried out as described pre-vector was produced by using 293A cells (Qbiogene), a subline of
293 cells (human embryonal kidney cells transformed by sheared viously [6].
adenovirus serotype 5 genome), and purified by two rounds of CsCl
gradient centrifugation, followed by removal of CsCl by dialysis Treatment of Adenoviral Vectors with PCB and WSPCB
against 10 mM Tris-Cl (pH 8.0), 2 mM MgCl2, 4% sucrose [8, 9]. The A stock solution of PCB (25 mg/ml in DMF) was diluted in PBS (pH
original preparation was diluted to 1  1010 viral particles/ml (1  7.4), and the diluted PCB (25 l) was added to 2.5  106 adenoviral
109 infectious units/ml) and stored at 70C until used. The dog vector particles (2.5  105 infectious units) in PBS (25 l). The
osteosarcoma cell line D-17 (ATCC number, CCL-183; American biotinylation reactions were performed on ice in the dark for 2 hr
Type Culture Collection) was maintained in DMEM supplemented and terminated by the addition of 100l DMEM/10% FBS. Treatment
with 6% FBS (BioWhittaker). of adenoviral vectors with WSPCB was performed in the same man-
ner, except that the WSPCB stock solution used had a concentration
of 100 mg/ml in DMF.Infectivity Assays
The infectivity of adenoviral vectors was determined by using D-17
Photoirradiation of WSPCB-Treated Adenoviral Vectorscells as targets, which are highly permissive to infection by adenovi-
Adenoviral vectors were treated with various concentrations ofral vectors. An adenoviral vector stock was placed over monolayers
WSPCB as above. WSPCB-treated viral vectors were divided intoof 5  104 D-17 cells in a 24-well plate and incubated at 37C for
two groups of borosilicate glass vials. One group of borosilicate24 hr. Cells were washed once with culture medium and incubated
glass vials was kept in the dark, while the other group was irradiatedat 37C for 24 hr to permit the expression of the lacZ gene. Cells were
for 3 min with 365 nm light using a UV lamp (model B-100 SP, UVthen fixed with 0.5% glutaraldehyde and stained for -galactosidase
Products) equipped with a 160 W mercury vapor bulb, which emitsactivity using X-gal (5-bromo-4-chloro-3-indolyl--D-galactopyran-
long-wavelength UV light in the 355–375 nm range, peaking at 365oside) as the substrate. Infected, lacZ-expressing cells (stained blue)
nm. Actual light intensities in this and other experiments were deter-were counted under a light microscope.
mined by using a UV light meter (model 06-662-65, UV Products).
The infectivity of the nonirradiated and irradiated adenoviral vectorsSynthesis of Photocleavable Biotinylation Reagents
was analyzed by using D-17 cells. The time course of the infectivityA photocleavable biotin (PCB; NHS-PC-LC-biotin) (Figure 1A) was
activation of WSPCB-treated adenoviral vectors upon photoirradia-synthesized as previously described [6]. A water-soluble derivative
tion was investigated in a similar manner, except that the exposureof PCB, WSPCB (Figure 1A), was synthesized by using the following
time to 365 nm light was varied.procedure (Figure 1B). All chemicals were obtained from Aldrich
except benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexa-
Western Blotting Analysisfluorophosphate (PyBOP), which was from Novabiochem. 5-Amino-
Adenoviral vectors, which had been treated with WSPCB as above,methyl-2-nitroacetophenone hydrochloride (1.73 g, 7.5 mmol) (com-
were placed in borosilicate glass vials (1.2  109 viral particles perpound 1) was dissolved in 60 ml of dimethylformamide (DMF). To
vial). One vial was kept in the dark, while the other vial was exposedthis solution, N,N-diisopropylethylamine (DIPEA; 1.2 ml), 2,6-
for 4 min to 365 nm light as above. Each of these viral samples wasdimethylaminopyridine (DMAP; 0.46 g, 3.75 mmol), and succinic
centrifuged at 25,000  g for 2 hr at 4C to precipitate adenoviralanhydride (0.75 g, 7.5 mmol) were added. The reaction mixture was
vectors. Viral precipitates were suspended in 10l of an SDS samplestirred at room temperature overnight, added to 120 ml of 0.1 M
solution containing 20 mM 2-mercaptoethanol and electrophoresedHCl, and extracted three times, each with 50 ml of chloroform.
on 4%–20% polyacrylamide gradient gels [10]. Proteins were trans-Organic extracts were combined, dried, and evaporated. Crude
ferred from the gel to polyvinylidene difluoride membrane (Millipore)products were recrystallized from acetonitrile to give compound 2
by using a semidry electroblotter. The membrane was blocked with(1.2 g, 49% yield). To a stirred solution of 2,2’-(ethylenedioxy)-bis-
SuperBlock (Pierce) and then incubated for 30 min with a strept-(ethylamine) (2 g; 13.5 mmol) (compound 3) in 100 ml of acetonitrile,
avidin-alkaline phosphatase conjugate (Pierce), diluted 5000-fold ina solution of 9-fluorenylmethoxycarbonyl N-hydroxysuccinimide
SuperBlock. Bound streptavidin-alkaline phosphatase conjugates(Fmoc-NHS; 4.95 g, 14.8 mmol) in 50 ml of acetonitrile was added
were visualized by alkaline phosphatase activity using nitroblue tet-over the course of 30 min. The reaction mixture was stirred for an
razolium chloride/5-bromo-4-chloro-3-indolylphosphate p-toluidineadditional 1 hr, concentrated under reduced pressure, and purified
salt (Pierce) as the substrates.on a silica gel using 0%–6% methanol step-gradient in chloroform/
0.8% triethylamine. Fractions containing a mono-Fmoc derivative
Virus Adsorption Assaywere pooled and evaporated to give 2.50 g of compound 4 (52%
Adenoviral vectors (1.25  109 viral particles per reaction) wereyield). To a stirred solution of compound 4 (2.5 g, 7 mmol) in 50 ml of
treated with 1 mg/ml WSPCB as above. The resulting viral vectorsmethanol, a solution of biotin-NHS (2.63 g, 7.7 mmol) in 60 ml of 95%
were either irradiated with 365 nm light (16 mW/cm2 ) for 3 min ormethanol was added over the course of 15 min. After 1 hr at room
kept in the dark. Each of these samples was added to a monolayertemperature, thin layer chromatography (chloroform/methanol/ace-
of D-17 cells cultured on a culture dish, and the mixtures weretic acid, 9:1:1 v/v/v) showed complete conversion into compound
incubated at 37C for 3 hr. The supernatant (culture medium fraction)5. The mixture was then concentrated under reduced pressure and
containing unbound adenoviral vectors was collected and irradiatedpurified on a silica gel using a 0%–6% methanol step-gradient in
with 365 nm light for 3 min as above (this irradiation step was omittedchloroform to give 2.2 g of compound 5 (54% yield). Compound 5
for adenoviral vectors that had been irradiated with 365 nm light).(2.2 g, 3.8 mmol) was added to 6 ml of 20% piperidine in DMF.
The infectivity of the resulting viral vectors was analyzed by usingThe resulting solution was stirred at room temperature for 10 min,
fresh D-17 cells to estimate the amount of adenoviral vectors thatconcentrated to about 2 ml under reduced pressure, and added to
remained unbound. Adenoviral vectors without WSPCB treatment20 ml of cold ether. After incubation at70C for 30 min, the precipi-
were used as controls. Nonspecific binding of adenoviral vectorstate was collected by centrifugation. The precipitate (compound 6)
was estimated by using empty culture dishes.was dissolved in 2 ml of methanol, reprecipitated as above, and
dried (yield 1.1 g, 82%). Compound 2 (5-succinylamidomethyl-2-
nitroacetophenone) (0.59 g, 1.94 mmol) was dissolved in 3 ml of In Vivo Activation of WSPCB-Treated Adenoviral Vectors
Mouse subcutaneous tumor models were prepared by using D-17DMF. To this solution, a solution of PyBOP (0.99 g, 1.94 mmol) in 3
ml DMF was added, followed by the addition of N,N-diisopropyl- cells and 9-week-old athymic nude mice (Hsd: Athymic Nude-nu/nu;
Harlan). D-17 cells (2 107 in 200l PBS per injection) were injectedethylamine (0.68 ml, 3.9 mmol). The resulting solution was stirred
at room temperature for 15 min, and then a solution of compound percutaneously on each side of the back of the mice just above the
upper legs. After 24 hr, small tumor nodules (3–5 mm) formed in6 (0.68 g, 1.94 mmol) in 3 ml DMF was added. Stirring continued
overnight, and solvents were evaporated under reduced pressure. these mice on both sides (at both injection sites). Adenoviral vectors
were treated with 0.5 mg/ml WSPCB as above. In vitro analysisThe residue was purified on a silica gel column using a 0%–20%
step-gradient of methanol in chloroform to give 0.75 g of compound using D-17 cells showed that the infectivity of the resulting WSPCB-
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treated viral vectors was inhibited to near completion and that the
infectivity can be reactivated efficiently upon irradiation of 365 nm
light.
Each tumor site of the mice was injected with 250 l of the
WSPCB-treated adenoviral vectors (2.3  109 infectious units prior
to the treatment) prepared above. After briefly massaging the injec-
tion sites, each mouse was anesthetized and covered with aluminum
foil with a hole to expose only the right-hand tumor sites. Exposed
tumor sites were irradiated at a distance of 12 cm with a 365 nm
UV lamp (model B-100SP) for two 2 min periods, separated by a 30
s intermission. Mice were maintained for 48 hr and then sacrificed,
followed by the collection of tumor sites with adjoining tissue. Tissue
was sectioned (50 m sections) in a CM 1850 Cryostat (Leica)
at 14C. Tissue sections were stained for the expression of the
lacZ gene using X-gal as the substrate, and the stained tissue sec-
tions were viewed under a light microscope. A control experiment
was performed in the same manner by injecting an equal amount
of unmodified adenoviral vectors into a tumor site.
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